Report cover image

Global Live Attenuated Rotavirus Vaccine Market Outlook and Growth Opportunities 2025

Publisher APO Research, Inc.
Published Jul 08, 2025
Length 198 Pages
SKU # APRC20280139

Description

Summary

According to APO Research, the global Live Attenuated Rotavirus Vaccine market is projected to grow from US$ million in 2025 to US$ million by 2031, at a compound annual growth rate (CAGR) of % during the forecast period.

The North American market for Live Attenuated Rotavirus Vaccine is estimated to increase from $ million in 2025 to reach $ million by 2031, at a CAGR of % during the forecast period of 2025 through 2031.

The Asia-Pacific market for Live Attenuated Rotavirus Vaccine is estimated to increase from $ million in 2025 to reach $ million by 2031, at a CAGR of % during the forecast period of 2025 through 2031.

In China, the Live Attenuated Rotavirus Vaccine market is expected to rise from $ million in 2025 to reach $ million by 2031, at a CAGR of % during the forecast period of 2025 through 2031.

The Europe market for Live Attenuated Rotavirus Vaccine is estimated to increase from $ million in 2025 to reach $ million by 2031, at a CAGR of % during the forecast period of 2025 through 2031.

Major global companies in the Live Attenuated Rotavirus Vaccine market include Bharat Biotech, GSK, Lanzhou Biological Products Research Institute and Merck Sharp & Dohme, etc. In 2024, the world's top three vendors accounted for approximately % of the revenue.

This report presents an overview of global market for Live Attenuated Rotavirus Vaccine, sales, revenue and price. Analyses of the global market trends, with historic market revenue or sales data for 2020 - 2024, estimates for 2025, and projections of CAGR through 2031.

This report researches the key producers of Live Attenuated Rotavirus Vaccine, also provides the sales of main regions and countries. Of the upcoming market potential for Live Attenuated Rotavirus Vaccine, and key regions or countries of focus to forecast this market into various segments and sub-segments. Country specific data and market value analysis for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, Middle East, Africa, and Other Countries.

This report focuses on the Live Attenuated Rotavirus Vaccine sales, revenue, market share and industry ranking of main manufacturers, data from 2020 to 2025. Identification of the major stakeholders in the global Live Attenuated Rotavirus Vaccine market, and analysis of their competitive landscape and market positioning based on recent developments and segmental revenues. This report will help stakeholders to understand the competitive landscape and gain more insights and position their businesses and market strategies in a better way.

This report analyzes the segments data by Type and by Application, sales, revenue, and price, from 2020 to 2031. Evaluation and forecast the market size for Live Attenuated Rotavirus Vaccine sales, projected growth trends, production technology, application and end-user industry.

Live Attenuated Rotavirus Vaccine Segment by Company

Bharat Biotech
GSK
Lanzhou Biological Products Research Institute
Merck Sharp & Dohme
Live Attenuated Rotavirus Vaccine Segment by Type

Monovalent Vaccines
Combination Vaccines
Live Attenuated Rotavirus Vaccine Segment by Application

Hospitals and Clinics
Vaccination Sites
Live Attenuated Rotavirus Vaccine Segment by Region

North America

United States
Canada
Mexico
Europe

Germany
France
U.K.
Italy
Russia
Spain
Netherlands
Switzerland
Sweden
Poland
Asia-Pacific

China
Japan
South Korea
India
Australia
Taiwan
Southeast Asia
South America

Brazil
Argentina
Chile
Colombia
Middle East & Africa

Egypt
South Africa
Israel
Türkiye
GCC Countries

Study Objectives

1. To analyze and research the global Live Attenuated Rotavirus Vaccine status and future forecast, involving, sales, revenue, growth rate (CAGR), market share, historical and forecast.
2. To present the key manufacturers, sales, revenue, market share, and Recent Developments.
3. To split the breakdown data by regions, type, manufacturers, and Application.
4. To analyze the global and key regions Live Attenuated Rotavirus Vaccine market potential and advantage, opportunity and challenge, restraints, and risks.
5. To identify Live Attenuated Rotavirus Vaccine significant trends, drivers, influence factors in global and regions.
6. To analyze Live Attenuated Rotavirus Vaccine competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Live Attenuated Rotavirus Vaccine market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.
2. This report will help stakeholders to understand the global industry status and trends of Live Attenuated Rotavirus Vaccine and provides them with information on key market drivers, restraints, challenges, and opportunities.
3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in sales and value), competitor ecosystem, new product development, expansion, and acquisition.
4. This report stays updated with novel technology integration, features, and the latest developments in the market.
5. This report helps stakeholders to gain insights into which regions to target globally.
6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Live Attenuated Rotavirus Vaccine.
7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Provides an overview of the Live Attenuated Rotavirus Vaccine market, including product definition, global market growth prospects, sales value, sales volume, and average price forecasts (2020-2031).
Chapter 2: Analysis key trends, drivers, challenges, and opportunities within the global Live Attenuated Rotavirus Vaccine industry.
Chapter 3: Detailed analysis of Live Attenuated Rotavirus Vaccine manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6: Sales and value of Live Attenuated Rotavirus Vaccine in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space, and market size of each country in the world.
Chapter 7: Sales and value of Live Attenuated Rotavirus Vaccine in country level. It provides sigmate data by type, and by application for each country/region.
Chapter 8: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 9: Analysis of industrial chain, including the upstream and downstream of the industry.
Chapter 10: Concluding Insights.

Please Note: Single-User license will be delivered via PDF from the publisher without the rights to print or to edit.

Table of Contents

198 Pages
1 Market Overview
1.1 Product Definition
1.2 Global Market Growth Prospects
1.2.1 Global Live Attenuated Rotavirus Vaccine Sales Value (2020-2031)
1.2.2 Global Live Attenuated Rotavirus Vaccine Sales Volume (2020-2031)
1.2.3 Global Live Attenuated Rotavirus Vaccine Sales Average Price (2020-2031)
1.3 Assumptions and Limitations
1.4 Study Goals and Objectives
2 Live Attenuated Rotavirus Vaccine Market Dynamics
2.1 Live Attenuated Rotavirus Vaccine Industry Trends
2.2 Live Attenuated Rotavirus Vaccine Industry Drivers
2.3 Live Attenuated Rotavirus Vaccine Industry Opportunities and Challenges
2.4 Live Attenuated Rotavirus Vaccine Industry Restraints
3 Live Attenuated Rotavirus Vaccine Market by Company
3.1 Global Live Attenuated Rotavirus Vaccine Company Revenue Ranking in 2024
3.2 Global Live Attenuated Rotavirus Vaccine Revenue by Company (2020-2025)
3.3 Global Live Attenuated Rotavirus Vaccine Sales Volume by Company (2020-2025)
3.4 Global Live Attenuated Rotavirus Vaccine Average Price by Company (2020-2025)
3.5 Global Live Attenuated Rotavirus Vaccine Company Ranking (2023-2025)
3.6 Global Live Attenuated Rotavirus Vaccine Company Manufacturing Base and Headquarters
3.7 Global Live Attenuated Rotavirus Vaccine Company Product Type and Application
3.8 Global Live Attenuated Rotavirus Vaccine Company Establishment Date
3.9 Market Competitive Analysis
3.9.1 Global Live Attenuated Rotavirus Vaccine Market Concentration Ratio (CR5 and HHI)
3.9.2 Global Top 5 and 10 Company Market Share by Revenue in 2024
3.9.3 2024 Live Attenuated Rotavirus Vaccine Tier 1, Tier 2, and Tier 3 Companies
3.10 Mergers and Acquisitions Expansion
4 Live Attenuated Rotavirus Vaccine Market by Type
4.1 Live Attenuated Rotavirus Vaccine Type Introduction
4.1.1 Monovalent Vaccines
4.1.2 Combination Vaccines
4.2 Global Live Attenuated Rotavirus Vaccine Sales Volume by Type
4.2.1 Global Live Attenuated Rotavirus Vaccine Sales Volume by Type (2020 VS 2024 VS 2031)
4.2.2 Global Live Attenuated Rotavirus Vaccine Sales Volume by Type (2020-2031)
4.2.3 Global Live Attenuated Rotavirus Vaccine Sales Volume Share by Type (2020-2031)
4.3 Global Live Attenuated Rotavirus Vaccine Sales Value by Type
4.3.1 Global Live Attenuated Rotavirus Vaccine Sales Value by Type (2020 VS 2024 VS 2031)
4.3.2 Global Live Attenuated Rotavirus Vaccine Sales Value by Type (2020-2031)
4.3.3 Global Live Attenuated Rotavirus Vaccine Sales Value Share by Type (2020-2031)
5 Live Attenuated Rotavirus Vaccine Market by Application
5.1 Live Attenuated Rotavirus Vaccine Application Introduction
5.1.1 Hospitals and Clinics
5.1.2 Vaccination Sites
5.2 Global Live Attenuated Rotavirus Vaccine Sales Volume by Application
5.2.1 Global Live Attenuated Rotavirus Vaccine Sales Volume by Application (2020 VS 2024 VS 2031)
5.2.2 Global Live Attenuated Rotavirus Vaccine Sales Volume by Application (2020-2031)
5.2.3 Global Live Attenuated Rotavirus Vaccine Sales Volume Share by Application (2020-2031)
5.3 Global Live Attenuated Rotavirus Vaccine Sales Value by Application
5.3.1 Global Live Attenuated Rotavirus Vaccine Sales Value by Application (2020 VS 2024 VS 2031)
5.3.2 Global Live Attenuated Rotavirus Vaccine Sales Value by Application (2020-2031)
5.3.3 Global Live Attenuated Rotavirus Vaccine Sales Value Share by Application (2020-2031)
6 Live Attenuated Rotavirus Vaccine Regional Sales and Value Analysis
6.1 Global Live Attenuated Rotavirus Vaccine Sales by Region: 2020 VS 2024 VS 2031
6.2 Global Live Attenuated Rotavirus Vaccine Sales by Region (2020-2031)
6.2.1 Global Live Attenuated Rotavirus Vaccine Sales by Region: 2020-2025
6.2.2 Global Live Attenuated Rotavirus Vaccine Sales by Region (2026-2031)
6.3 Global Live Attenuated Rotavirus Vaccine Sales Value by Region: 2020 VS 2024 VS 2031
6.4 Global Live Attenuated Rotavirus Vaccine Sales Value by Region (2020-2031)
6.4.1 Global Live Attenuated Rotavirus Vaccine Sales Value by Region: 2020-2025
6.4.2 Global Live Attenuated Rotavirus Vaccine Sales Value by Region (2026-2031)
6.5 Global Live Attenuated Rotavirus Vaccine Market Price Analysis by Region (2020-2025)
6.6 North America
6.6.1 North America Live Attenuated Rotavirus Vaccine Sales Value (2020-2031)
6.6.2 North America Live Attenuated Rotavirus Vaccine Sales Value Share by Country, 2024 VS 2031
6.7 Europe
6.7.1 Europe Live Attenuated Rotavirus Vaccine Sales Value (2020-2031)
6.7.2 Europe Live Attenuated Rotavirus Vaccine Sales Value Share by Country, 2024 VS 2031
6.8 Asia-Pacific
6.8.1 Asia-Pacific Live Attenuated Rotavirus Vaccine Sales Value (2020-2031)
6.8.2 Asia-Pacific Live Attenuated Rotavirus Vaccine Sales Value Share by Country, 2024 VS 2031
6.9 South America
6.9.1 South America Live Attenuated Rotavirus Vaccine Sales Value (2020-2031)
6.9.2 South America Live Attenuated Rotavirus Vaccine Sales Value Share by Country, 2024 VS 2031
6.10 Middle East & Africa
6.10.1 Middle East & Africa Live Attenuated Rotavirus Vaccine Sales Value (2020-2031)
6.10.2 Middle East & Africa Live Attenuated Rotavirus Vaccine Sales Value Share by Country, 2024 VS 2031
7 Live Attenuated Rotavirus Vaccine Country-level Sales and Value Analysis
7.1 Global Live Attenuated Rotavirus Vaccine Sales by Country: 2020 VS 2024 VS 2031
7.2 Global Live Attenuated Rotavirus Vaccine Sales Value by Country: 2020 VS 2024 VS 2031
7.3 Global Live Attenuated Rotavirus Vaccine Sales by Country (2020-2031)
7.3.1 Global Live Attenuated Rotavirus Vaccine Sales by Country (2020-2025)
7.3.2 Global Live Attenuated Rotavirus Vaccine Sales by Country (2026-2031)
7.4 Global Live Attenuated Rotavirus Vaccine Sales Value by Country (2020-2031)
7.4.1 Global Live Attenuated Rotavirus Vaccine Sales Value by Country (2020-2025)
7.4.2 Global Live Attenuated Rotavirus Vaccine Sales Value by Country (2026-2031)
7.5 USA
7.5.1 USA Live Attenuated Rotavirus Vaccine Sales Value Growth Rate (2020-2031)
7.5.2 USA Live Attenuated Rotavirus Vaccine Sales Value Share by Type, 2024 VS 2031
7.5.3 USA Live Attenuated Rotavirus Vaccine Sales Value Share by Application, 2024 VS 2031
7.6 Canada
7.6.1 Canada Live Attenuated Rotavirus Vaccine Sales Value Growth Rate (2020-2031)
7.6.2 Canada Live Attenuated Rotavirus Vaccine Sales Value Share by Type, 2024 VS 2031
7.6.3 Canada Live Attenuated Rotavirus Vaccine Sales Value Share by Application, 2024 VS 2031
7.7 Mexico
7.6.1 Mexico Live Attenuated Rotavirus Vaccine Sales Value Growth Rate (2020-2031)
7.6.2 Mexico Live Attenuated Rotavirus Vaccine Sales Value Share by Type, 2024 VS 2031
7.6.3 Mexico Live Attenuated Rotavirus Vaccine Sales Value Share by Application, 2024 VS 2031
7.8 Germany
7.8.1 Germany Live Attenuated Rotavirus Vaccine Sales Value Growth Rate (2020-2031)
7.8.2 Germany Live Attenuated Rotavirus Vaccine Sales Value Share by Type, 2024 VS 2031
7.8.3 Germany Live Attenuated Rotavirus Vaccine Sales Value Share by Application, 2024 VS 2031
7.9 France
7.9.1 France Live Attenuated Rotavirus Vaccine Sales Value Growth Rate (2020-2031)
7.9.2 France Live Attenuated Rotavirus Vaccine Sales Value Share by Type, 2024 VS 2031
7.9.3 France Live Attenuated Rotavirus Vaccine Sales Value Share by Application, 2024 VS 2031
7.10 U.K.
7.10.1 U.K. Live Attenuated Rotavirus Vaccine Sales Value Growth Rate (2020-2031)
7.10.2 U.K. Live Attenuated Rotavirus Vaccine Sales Value Share by Type, 2024 VS 2031
7.10.3 U.K. Live Attenuated Rotavirus Vaccine Sales Value Share by Application, 2024 VS 2031
7.11 Italy
7.11.1 Italy Live Attenuated Rotavirus Vaccine Sales Value Growth Rate (2020-2031)
7.11.2 Italy Live Attenuated Rotavirus Vaccine Sales Value Share by Type, 2024 VS 2031
7.11.3 Italy Live Attenuated Rotavirus Vaccine Sales Value Share by Application, 2024 VS 2031
7.12 Spain
7.12.1 Spain Live Attenuated Rotavirus Vaccine Sales Value Growth Rate (2020-2031)
7.12.2 Spain Live Attenuated Rotavirus Vaccine Sales Value Share by Type, 2024 VS 2031
7.12.3 Spain Live Attenuated Rotavirus Vaccine Sales Value Share by Application, 2024 VS 2031
7.13 Russia
7.13.1 Russia Live Attenuated Rotavirus Vaccine Sales Value Growth Rate (2020-2031)
7.13.2 Russia Live Attenuated Rotavirus Vaccine Sales Value Share by Type, 2024 VS 2031
7.13.3 Russia Live Attenuated Rotavirus Vaccine Sales Value Share by Application, 2024 VS 2031
7.14 Netherlands
7.14.1 Netherlands Live Attenuated Rotavirus Vaccine Sales Value Growth Rate (2020-2031)
7.14.2 Netherlands Live Attenuated Rotavirus Vaccine Sales Value Share by Type, 2024 VS 2031
7.14.3 Netherlands Live Attenuated Rotavirus Vaccine Sales Value Share by Application, 2024 VS 2031
7.15 Nordic Countries
7.15.1 Nordic Countries Live Attenuated Rotavirus Vaccine Sales Value Growth Rate (2020-2031)
7.15.2 Nordic Countries Live Attenuated Rotavirus Vaccine Sales Value Share by Type, 2024 VS 2031
7.15.3 Nordic Countries Live Attenuated Rotavirus Vaccine Sales Value Share by Application, 2024 VS 2031
7.16 China
7.16.1 China Live Attenuated Rotavirus Vaccine Sales Value Growth Rate (2020-2031)
7.16.2 China Live Attenuated Rotavirus Vaccine Sales Value Share by Type, 2024 VS 2031
7.16.3 China Live Attenuated Rotavirus Vaccine Sales Value Share by Application, 2024 VS 2031
7.17 Japan
7.17.1 Japan Live Attenuated Rotavirus Vaccine Sales Value Growth Rate (2020-2031)
7.17.2 Japan Live Attenuated Rotavirus Vaccine Sales Value Share by Type, 2024 VS 2031
7.17.3 Japan Live Attenuated Rotavirus Vaccine Sales Value Share by Application, 2024 VS 2031
7.18 South Korea
7.18.1 South Korea Live Attenuated Rotavirus Vaccine Sales Value Growth Rate (2020-2031)
7.18.2 South Korea Live Attenuated Rotavirus Vaccine Sales Value Share by Type, 2024 VS 2031
7.18.3 South Korea Live Attenuated Rotavirus Vaccine Sales Value Share by Application, 2024 VS 2031
7.19 India
7.19.1 India Live Attenuated Rotavirus Vaccine Sales Value Growth Rate (2020-2031)
7.19.2 India Live Attenuated Rotavirus Vaccine Sales Value Share by Type, 2024 VS 2031
7.19.3 India Live Attenuated Rotavirus Vaccine Sales Value Share by Application, 2024 VS 2031
7.20 Australia
7.20.1 Australia Live Attenuated Rotavirus Vaccine Sales Value Growth Rate (2020-2031)
7.20.2 Australia Live Attenuated Rotavirus Vaccine Sales Value Share by Type, 2024 VS 2031
7.20.3 Australia Live Attenuated Rotavirus Vaccine Sales Value Share by Application, 2024 VS 2031
7.21 Southeast Asia
7.21.1 Southeast Asia Live Attenuated Rotavirus Vaccine Sales Value Growth Rate (2020-2031)
7.21.2 Southeast Asia Live Attenuated Rotavirus Vaccine Sales Value Share by Type, 2024 VS 2031
7.21.3 Southeast Asia Live Attenuated Rotavirus Vaccine Sales Value Share by Application, 2024 VS 2031
7.22 Brazil
7.22.1 Brazil Live Attenuated Rotavirus Vaccine Sales Value Growth Rate (2020-2031)
7.22.2 Brazil Live Attenuated Rotavirus Vaccine Sales Value Share by Type, 2024 VS 2031
7.22.3 Brazil Live Attenuated Rotavirus Vaccine Sales Value Share by Application, 2024 VS 2031
7.23 Argentina
7.23.1 Argentina Live Attenuated Rotavirus Vaccine Sales Value Growth Rate (2020-2031)
7.23.2 Argentina Live Attenuated Rotavirus Vaccine Sales Value Share by Type, 2024 VS 2031
7.23.3 Argentina Live Attenuated Rotavirus Vaccine Sales Value Share by Application, 2024 VS 2031
7.24 Chile
7.24.1 Chile Live Attenuated Rotavirus Vaccine Sales Value Growth Rate (2020-2031)
7.24.2 Chile Live Attenuated Rotavirus Vaccine Sales Value Share by Type, 2024 VS 2031
7.24.3 Chile Live Attenuated Rotavirus Vaccine Sales Value Share by Application, 2024 VS 2031
7.25 Colombia
7.25.1 Colombia Live Attenuated Rotavirus Vaccine Sales Value Growth Rate (2020-2031)
7.25.2 Colombia Live Attenuated Rotavirus Vaccine Sales Value Share by Type, 2024 VS 2031
7.25.3 Colombia Live Attenuated Rotavirus Vaccine Sales Value Share by Application, 2024 VS 2031
7.26 Peru
7.26.1 Peru Live Attenuated Rotavirus Vaccine Sales Value Growth Rate (2020-2031)
7.26.2 Peru Live Attenuated Rotavirus Vaccine Sales Value Share by Type, 2024 VS 2031
7.26.3 Peru Live Attenuated Rotavirus Vaccine Sales Value Share by Application, 2024 VS 2031
7.27 Saudi Arabia
7.27.1 Saudi Arabia Live Attenuated Rotavirus Vaccine Sales Value Growth Rate (2020-2031)
7.27.2 Saudi Arabia Live Attenuated Rotavirus Vaccine Sales Value Share by Type, 2024 VS 2031
7.27.3 Saudi Arabia Live Attenuated Rotavirus Vaccine Sales Value Share by Application, 2024 VS 2031
7.28 Israel
7.28.1 Israel Live Attenuated Rotavirus Vaccine Sales Value Growth Rate (2020-2031)
7.28.2 Israel Live Attenuated Rotavirus Vaccine Sales Value Share by Type, 2024 VS 2031
7.28.3 Israel Live Attenuated Rotavirus Vaccine Sales Value Share by Application, 2024 VS 2031
7.29 UAE
7.29.1 UAE Live Attenuated Rotavirus Vaccine Sales Value Growth Rate (2020-2031)
7.29.2 UAE Live Attenuated Rotavirus Vaccine Sales Value Share by Type, 2024 VS 2031
7.29.3 UAE Live Attenuated Rotavirus Vaccine Sales Value Share by Application, 2024 VS 2031
7.30 Turkey
7.30.1 Turkey Live Attenuated Rotavirus Vaccine Sales Value Growth Rate (2020-2031)
7.30.2 Turkey Live Attenuated Rotavirus Vaccine Sales Value Share by Type, 2024 VS 2031
7.30.3 Turkey Live Attenuated Rotavirus Vaccine Sales Value Share by Application, 2024 VS 2031
7.31 Iran
7.31.1 Iran Live Attenuated Rotavirus Vaccine Sales Value Growth Rate (2020-2031)
7.31.2 Iran Live Attenuated Rotavirus Vaccine Sales Value Share by Type, 2024 VS 2031
7.31.3 Iran Live Attenuated Rotavirus Vaccine Sales Value Share by Application, 2024 VS 2031
7.32 Egypt
7.32.1 Egypt Live Attenuated Rotavirus Vaccine Sales Value Growth Rate (2020-2031)
7.32.2 Egypt Live Attenuated Rotavirus Vaccine Sales Value Share by Type, 2024 VS 2031
7.32.3 Egypt Live Attenuated Rotavirus Vaccine Sales Value Share by Application, 2024 VS 2031
8 Company Profiles
8.1 Bharat Biotech
8.1.1 Bharat Biotech Comapny Information
8.1.2 Bharat Biotech Business Overview
8.1.3 Bharat Biotech Live Attenuated Rotavirus Vaccine Sales, Value and Gross Margin (2020-2025)
8.1.4 Bharat Biotech Live Attenuated Rotavirus Vaccine Product Portfolio
8.1.5 Bharat Biotech Recent Developments
8.2 GSK
8.2.1 GSK Comapny Information
8.2.2 GSK Business Overview
8.2.3 GSK Live Attenuated Rotavirus Vaccine Sales, Value and Gross Margin (2020-2025)
8.2.4 GSK Live Attenuated Rotavirus Vaccine Product Portfolio
8.2.5 GSK Recent Developments
8.3 Lanzhou Biological Products Research Institute
8.3.1 Lanzhou Biological Products Research Institute Comapny Information
8.3.2 Lanzhou Biological Products Research Institute Business Overview
8.3.3 Lanzhou Biological Products Research Institute Live Attenuated Rotavirus Vaccine Sales, Value and Gross Margin (2020-2025)
8.3.4 Lanzhou Biological Products Research Institute Live Attenuated Rotavirus Vaccine Product Portfolio
8.3.5 Lanzhou Biological Products Research Institute Recent Developments
8.4 Merck Sharp & Dohme
8.4.1 Merck Sharp & Dohme Comapny Information
8.4.2 Merck Sharp & Dohme Business Overview
8.4.3 Merck Sharp & Dohme Live Attenuated Rotavirus Vaccine Sales, Value and Gross Margin (2020-2025)
8.4.4 Merck Sharp & Dohme Live Attenuated Rotavirus Vaccine Product Portfolio
8.4.5 Merck Sharp & Dohme Recent Developments
9 Value Chain and Sales Channels Analysis
9.1 Live Attenuated Rotavirus Vaccine Value Chain Analysis
9.1.1 Live Attenuated Rotavirus Vaccine Key Raw Materials
9.1.2 Raw Materials Key Suppliers
9.1.3 Manufacturing Cost Structure
9.1.4 Live Attenuated Rotavirus Vaccine Sales Mode & Process
9.2 Live Attenuated Rotavirus Vaccine Sales Channels Analysis
9.2.1 Direct Comparison with Distribution Share
9.2.2 Live Attenuated Rotavirus Vaccine Distributors
9.2.3 Live Attenuated Rotavirus Vaccine Customers
10 Concluding Insights
11 Appendix
11.1 Reasons for Doing This Study
11.2 Research Methodology
11.3 Research Process
11.4 Authors List of This Report
11.5 Data Source
11.5.1 Secondary Sources
11.5.2 Primary Sources
How Do Licenses Work?
Head shot

Questions or Comments?

Our team has the ability to search within reports to verify it suits your needs. We can also help maximize your budget by finding sections of reports you can purchase.